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NCCM is a rare cardiomyopathy with unknown origin which is frequently associ-
ated with specific genetic abnormalities [1]. NCCM affects mostly the LV, and 
hypothesized to be resulting from the arrest of the normal compaction process of the 
myocardium during foetal development [2]. NCCM is characterized by prominent 
myocardial trabeculations and deep intertrabecular recesses in the LV cavity [3]. 
Due to its special phenotype, typical potential complications are heart failure, 
arrhythmias, and thromboembolic events.
 Diagnosis of Noncompaction Cardiomyopathy
The diagnosis of NCCM is mostly based on echocardiography, although its limita-
tions are widely known. For a comprehensive overview, we refer to Chap. 3.
Several echocardiographic criteria are used in the clinical practice, the most 
known criteria were created by Chin [4], Jenni [5], Stöllberger [6] and Belanger [7]. 
Although echocardiography is considered to be the gold-standard imaging technol-
ogy in the diagnosis of NCCM, Diwadkar et al. found that echocardiography fails to 
detect NCCM morphology/hypertrabeculation in a significant number of a cohort of 
patients on cardiac magnetic resonance imaging (cMRI) in a recent study [8]. These 
findings suggest ambiguous results in the diagnosis of NCCM, making the real 
prevalence of NCCM more complicated.
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Case 1: A Patient with Noncompaction Cardiomyopathy
A case of a 50-year-old female patient is presented. Muscular ventricular septal 
defect and persistent foramen ovale are present in her medical history with chronic 
heart failure originating from familiar NCCM. At the age of 40, the patient suffered 
a cerebrovascular accident with mild hemiparesis. Oral anticoagulation was pre-
scribed along with optimization of her heart failure medication. Four years later, 
there was a suspected transient ischaemic attack. In 2015, a VDD-ICD was implanted 
for primary prevention for cardiac death; the intervention was complicated with 
right ventricular perforation, pericardial effusion and dislocation of the VDD lead. 
Recently, her functional class was in New York Heart Association functional grade 
I, routine two-dimensional Doppler echocardiography confirmed reduced LV sys-
tolic function with ejection fraction of approximately 30–35% and grade 2 diastolic 
dysfunction (E/E′ proved to be 14.3) without significant valvular regurgitation or 
stenosis (Figs. 6.1 and 6.2). Wall motion analysis confirmed diffuse LV hypokinesis 
with inferior basal and midventricular akinesis (wall motion score index = 2.24), 
The right ventricular function proved to be normal. Electrocardiography (ECG) did 
not confirm significant arrhythmia (Fig. 6.3).










Fig. 6.2 Colour Doppler echocardiographic images demonstrating intertrabecular recesses (see 
white arrows)
Fig. 6.3 Routine electrocardiography demonstrating normofrequent sinus rhythm without signifi-
cant arrhythmia or conductance disorder
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 Prevalence of Noncompaction Cardiomyopathy
The true prevalence of NCCM in the general population would be determined 
based on population-based echocardiographic screening. However, there are no 
population- based studies to determine the real prevalence of NCCM [1]. The first 
prospective and large echocardiography-based study to determine the real preva-
lence of NCCM has just been published [1]. This prospective case-control study 
included all subjects who underwent a transthoracic echocardiogram in an aca-
demic center within one-year [1]. From 10,857 echocardiograms performed, 26 
cases of NCCM were detected giving an estimated prevalence of 0.24% for this 
cohort [1]. Most patients (77%) had ≤50% LV ejection fraction in higher ages. 
When cases with dilated cardiomyopathies of different aetiologies were analysed, 
6.8% of the cases showed NCCM with EF <50%. When only those patients with 
idiopathic dilated cardiomyopathy were included, the estimated prevalence of 
NCCM was 24%. When LV noncompaction was detected only incidentally in an 
otherwise healthy and asymptomatic population with normal ejection fraction, the 
prevalence was 0.05% [1]. In a recent study by Ivanov et  al., a cohort of 700 
patients referred for cMRI underwent diagnostic assessment for NCCM by four 
separate imaging criteria referenced by their authors as Petersen, Stacey, Jacquier, 
and Captur, with a NCCM prevalence of 39%, 23%, 25% and 3%, respectively [9]. 
In the childhood, large paediatric studies have found NCCM to be the most com-
mon form of unclassified cardiomyopathies [10, 11].
 Prevalence of Thromboembolic Events in Noncompaction 
Cardiomyopathy
There are conflicting results about the prevalence of the most feared NCCM-
related complications, the thromboembolic events in NCCM, but these complica-
tions seem to be not uncommon in NCCM. Cardiac emboli are theorized to result 
from thrombus formation within the intertrabecular recesses, but reduced sys-
tolic function predispose to thrombosis as well. The higher risk of arrhythmias, 
including atrial fibrillation (AF) is also considerable source of the evolution of 
thromboembolism in NCCM [12]. The other important risk factors for thrombo-
embolic events are previous thromboembolic events, hypertension, coagulopa-
thy, etc. [13, 14]. According to the literature, stroke and embolism occur in at 
least 15% of patients with NCCM due to above mentioned reasons [14]. However, 
it should also be considered that in cases of NCCM with AF, thrombi may not 
only be derived from the intertrabecular spaces but also from the left atrium or 
left atrial appendage [15]. The overall thromboembolic annualized event rate is 
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 Anticoagulant Treatment for Stroke Prevention in General 
Cardiac Patients
Oral anticoagulant therapy (OAC) prevents the majority of ischaemic strokes in 
patient with AF and is confirmed to prolong life [17]. Men with a CHA2DS2-VASc 
of 2 or more and women with a CHA2DS2-VASc score of 3 or more are suggested 
to benefit from OAC. Therefore, OAC should be considered from a CHA2DS2-VASc 
of 1  in men and 2  in women considering the potential adverse events, including 
bleeding risks and the patients’ preference. Vitamin K antagonists (VKA), the first 
anticoagulants used in patients with AF were confirmed to reduce the risk of stroke 
by two-thirds and to reduce mortality by 25% compared with control. VKA therapy 
is limited by the narrow therapeutic range of VKAs, the need for close monitoring 
and potential dose adjustments. Non-vitamin K type oral anticoagulants (NOACs), 
including the direct thrombin inhibitor dabigatran and the factor Xa inhibitors, apix-
aban, edoxaban and rivaroxaban, are suitable alternative treatment options to VKAs 
for stroke prevention in patients with AF. NOACs have a predictable effect (onset 
and offset), no regular laboratory test is required to test the efficacy of NOACs. 
NOACs are recommended in preference to VKAs or acetylsalicylic acid in AF 
patients with a previous stroke [17].
In patients with heart failure with reduced ejection fraction (HFrEF) or preserved 
EF (HFpEF) however, there is no evidence that the use of warfarin reduces mortality 
and morbidity as compared to placebo or acetylsalicylic acid [18]. Therefore, new 
studies with NOACs in patients with HFrEF are ongoing.
 Anticoagulation Therapy for Stroke Prevention in Noncompaction 
Cardiomyopathy Patients
It is generally recommended to those presenting with antecedent of systemic embo-
lism, presence of cardiac thrombus and AF and ventricular systolic dysfunction [19]. 
Unfortunately, due to its rarity, evidence-based recommendations for preventing 
thromboembolic events in isolated NCCM have not been established. It is still not 
clear under which conditions NCCM patients should be clearly anticoagulated for 
primary prophylaxis of stroke or embolism. According to the latest literature on how 
to use anticoagulants in LV noncompaction, the recommendations are the following:
• If NCCM is associated with AF, the usefulness of anticoagulants seem to be 
reasonable by reducing thromboembolic rate including vitamin K-antagonists 
(VKA) and new oral anticoagulants (NOAC) [15, 20].
• If NCCM is associated with a history of previous stroke and embolism, VKA or 
NOAC should be considered [15, 20].
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• If NCCM is associated with systolic dysfunction and sinus rhythm, no significant 
overall difference could be demonstrated in the primary outcome between treat-
ment with VKA and high dose acetylsalicylic acid [21]. Anticoagulant treatment 
in these patients without history of previous thromboembolism is still on debate. 
Given the deep intertrabecular recesses and probably slurred local slow flows, 
historically the NCCM patients has been always considered as high-risk patients 
for thromboembolic events. Therefore, till we have more clear and specific evi-
dence, we advise in general anticoagulation therapy in NCCM patients with sig-
nificant LV dysfunction (i.e. empirically LVEF <40%) and/or heart failure.
To understand the potential indications of anticoagulation therapy in noncom-
paction cardiomyopathy, here some cases are presented.
Case 2: A Patient with Noncompaction Cardiomyopathy with Atrial 
Fibrillation
A case of a 35-year-old male patient is presented. His medical history started with pal-
pitations at the age of 32, when electrocardiography (ECG) showed sinus rhythm. 
Routine transthoracic Doppler echocardiography revealed mildly enlarged LV and atria 
without significant valvular alterations. LV ejection fraction was 60%, grade 2 diastolic 
dysfunction could be confirmed with normal RV sizes and function. With Doppler echo-
cardiography, deeply perfused intertrabecular recesses could be demonstrated suggest-
ing NCCM (Fig. 6.4). The patients did not show any signs of heart failure. But Holter 
ECG showed paroxysmal atrial fibrillation (Fig. 6.5). Therefore, oral anticoagulation 
was initiated.
Fig. 6.4 Routine 2-dimensional echocardiography of a 35-year-old male demonstrating hypertra-
becularization of the LV apex with intertrabecular recesses (see white arrows)
A. Nemes
91
Case 3: A Patient with Noncompaction Cardiomyopathy  
with Systolic Dysfunction
A 58-year-old male presented with shortness of breath on exertion and atypical 
chest pain. His past medical history consisted of mild mitral regurgitation, hyperlip-
idemia, and osteoporosis. His present symptoms started 1 month ago, with chest 
X-ray showing cardiomegaly. ECG showed sinus rhythm with normal heart rate 
(Fig. 6.6). Two-dimensional transthoracic echocardiography revealed signs of LV 
hypertrophy with diffuse myocardial lesion and reduced LV function (ejection frac-
tion: 37%) could be demonstrated by. But, detailed echocardiographic evaluation of 
the thickened myocardial walls showed hypertrabecularization of the LV apex and 
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Fig. 6.6 Routine 2-dimensional echocardiography demonstrating hypertrabecularization of the 
LV apex with intertrabecular recesses
Fig. 6.7 Routine electrocardiography demonstrating normofrequent sinus rhythm without signifi-
cant arrhythmia or conductance disorder
septum rather than LV hypertrophy. Colour Doppler echocardiography confirmed 
intertrabecular recesses, confirming the diagnosis of NCCM (Fig. 6.7). Given the 
significant LV dysfunction with a LVEF <40%, we prescribed empirically oral anti-




Thromboembolic events are relatively common in NCCM patients. Unfortunately, 
due to its rarity and relatively young disease entity, evidence-based recommenda-
tions for preventing thromboembolic events in NCCM have not been established. In 
patients with atrial fibrillation or flutter oral anticoagulation including vitamin K 
antagonists (VKA) and new oral anticoagulants (NOAC), seem to be reasonable to 
reduce thromboembolic rate. In case of a history of previous stroke and thromboem-
bolism, VKA or NOAC use is according the current clinical insights beyond any 
doubt. In NCCM patient with an systolic dysfunction, but sinus rhythm, overall 
benefit of preventive oral anticoagulation is yet to be demonstrated. Further research 
for evidence-based guidelines are highly needed.
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